Patients with Myotonic Dystrophy type 1 exhibit a diversity of symptoms that affect many different organs. Among those are cognitive dysfunctions, the origin of which has remained elusive due in part to the difficulty in accessing neural cells. Here, we have taken advantage of pluripotent stem cell lines derived from embryos identified during a pre-implantation genetic diagnosis as mutant gene-carriers, in order to differentiate cells along the neural lineage. Functional characterization of these cells revealed reduced proliferative capacity and increased autophagy linked to mTOR signaling pathway alterations. Interestingly, loss of function of MBNL1, a RNA-binding protein whose function is defective in DM1 patients, resulted in the mTOR signaling alteration whereas gain-of-function experiments rescued the phenotype. Collectively, these results provide a mechanism by which DM1 mutation might affect a major signaling pathway and highlight the pertinence of using pluripotent stem cells to study neuronal defects. T. (1994). Involvement of the central nervous system in myotonic dystrophy. J Neurol Sci 127, 179-85. Beffy, P., Del Carratore, R., Masini, M., Furling, D., Puymirat, J., Masiello, P. and Simili, M. (2010). Altered signal transduction pathways and induction of autophagy in human myotonic dystrophy type 1 myoblasts. , M. M., Xia, G. et al. (2012). Muscleblind-like 2-mediated alternative splicing in the developing brain and dysregulation in myotonic dystrophy. Neuron 75, 437-50. Dansithong, W., Paul, S., Comai, L. and Reddy, S. (2005). MBNL1 is the primary determinant of focus formation and aberrant insulin receptor splicing in DM1. J Biol Chem 280, 5773-80. de Leon, M. B. and Cisneros, B. (2008). Myotonic dystrophy 1 in the nervous system: from the clinic to molecular mechanisms. J Neurosci Res 86, 18-26. Delaporte, C. (1998). Personality patterns in patients with myotonic dystrophy. Arch Neurol 55, 635-40.
INTRODUCTION
Due to their ability to differentiate into a large spectrum of cell types, human diseasespecific pluripotent stem cells, of embryonic origin (hESCs) or more recently derived from the reprogramming of somatic cells (hiPSCs), appear to be a unique material to correlate molecular and functional pathological mechanisms within difficult-to-obtain cell populations (Gauthier et al., 2012; . In the context of human neurological disorders, most of our current knowledge about molecular and cellular phenotypes has been gathered from studies in postmortem brain tissues, which typically the end-stage of the disease and consequently may not be a fair illustration of how the disease developed. Human diseasespecific pluripotent stem cells provide a unique opportunity to complement these data by analyzing the first stages of disease progression and to decipher molecular mechanisms that could be at the origin of a disease-related functional phenotype.
Over the past years, a growing number of studies have demonstrated this application both for neurodevelopmental and neurodegenerative disorders. Pre-implantation genetically diagnosed embryos have, for instance, allowed molecular and functional defects in hESCsderived neurons carrying a mutant gene responsible for fragile X (Eiges et al., 2007) and in motoneurons with myotonic dystrophy type 1 (DM1) (Marteyn et al., 2011) to be analyzed.
Other young childhood-onset monogenic disorders, such as the Rett syndrome, familial dysautonomia disorder and spinal muscular atrophy, have been studied following the generation of hiPSCs from patients, and a defective neuronal phenotype associated with the expression of the mutant gene (Ebert et al., 2009; Kim et al., 2011; Lee et al., 2009) . Human iPSCs have also been instrumental in deciphering a familial case of the late-onset neurodegenerative Parkinson's disease, associating the expression of a mutant gene with an increased sensitivity of hiPSCs-derived dopamine neurons to oxidative stress (Seibler et al., 2011) .
Myotonic dystrophy type 1 is an autosomal dominant neuromuscular disorder with late clinical onset, caused by the expansion of trinucleotide CTG repeats in the 3'-untranslated region of the DMPK gene (Mahadevan et al., 1992) . At the skeletal muscle level, three main molecular events can be described: 1) formation of nuclear foci that are composed at least of mutant DMPK mRNA and recruited RNA binding proteins, such as splicing regulators and transcription factors (Ebralidze et al., 2004; Mankodi et al., 2001; Timchenko and Caskey, 1996) ; 2) disturbance of specific gene expression (Mankodi et al., 2002; Savkur et al., 2001; Yadava et al., 2008) ; and 3) impairment of cell proliferation and differentiation (Bigot et al., 2009; Furling et al., 2001; Timchenko et al., 2001a) . Although DM1 has long been mainly considered as a muscle disorder, there is extensive evidence for involvement of the central nervous system. Psychological dysfunction, mental retardation, excessive daytime sleepiness, and neuropathological abnormalities have been described in DM1 patients (Abe et al., 1994; Delaporte, 1998; Modoni et al., 2004; Modoni et al., 2008; Perini et al., 1999; Turnpenny et al., 1994) . Nevertheless, in contrast with the substantial advances in understanding DM1 muscle pathology, the molecular and functional bases of DM1 in the central nervous system are still largely unknown.
In looking for molecular and functional mechanisms that could be implicated in neural development in DM1, we based our approach upon DM1-specific human pluripotent stem cells and their ability to differentiate into neural cells. We recently demonstrated that human embryonic stem cells (hESCs) obtained during pre-implantation genetic diagnosis for DM1 (Mateizel et al., 2006) represent a relevant cellular model for DM1. In particular, these human DM1 specific pluripotent stem cells have allowed us, to discover new molecular mechanisms impeding the connectivity between DM1 hESCs-derived motor neurons and their muscle targets (Marteyn et al., 2011) . To more broadly analyze the molecular and functional effects of the DM1 mutation in neural cells, we have taken advantage of progress made in neural differentiation protocols to obtain robust and homogenous neural precursor cell populations (Chambers et al., 2009) . We show here that these neural cells exhibit a proliferative deficiency linked to a DM1-related impairment in mTOR signaling pathway activity, associated with increased autophagy.
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RESULTS
Two human embryonic stem cell lines (hES) carrying large CTG expansions (VUB03_DM and VUB24_DM) obtained from independent couples, and one wild type control cell line (VUB01_WT) were successfully differentiated toward a homogenous population of neural stem cells (NSCs). No differences in morphology and in the expression of NSC-specific markers such as Nestin and Sox2 were observed during the differentiation process ( Fig. 1a-c) .
Moreover, no differences in neuronal differentiation were observed between control and mutant cells at day 20 for most of the analyzed gene markers, such as SNAP25, DLG4 and MAPT, although we cannot completely exclude a difference between DM1 and WT over the time course of neuronal differentiation (Supp. Fig. S1 ). Validating their pathological relevance, in situ hybridization combined with immunostaining indicated that DM1-NSCs and derived-neurons harbored intranuclear ribonucleoprotein aggregates (named "foci") formed by the mutant RNA and the splice factor MBNL1, which are typical of the disease (Fig. 1d) .
The nuclear retention of MBNL1 was also confirmed by western blot (Fig. 1e ).
Functional consequences of DM1 in neural stem cells
Quantitative analysis of doubling time through measurement of the ATP concentration in cell cultures indicated that the proliferation rate of DM1-NSCs was reduced when compared to controls ( Fig. 2a and 2b) . Consistent with this observation, a decreased number of Ki67 positive cells was observed in DM1-NSC cultures (Fig. 2c) , in association with decreased PCNA gene expression and decreased phosphorylation of the Rb protein ( Fig. 2d and 2e ). In addition, expression of other cell cycle regulators was deregulated in DM1 cells in comparison with control, with increased p27 kip1 (Fig. 2f ) and P15 proteins and decreased Cyclin D1 and P21 (Fig. 2g ).
Measurement of necrosis or apoptosis by annexinV and propidium iodide staining, PARP cleavage and caspase-3 expression revealed no differences between DM1 and WT NSCs.
Similarly, β−galactosidase staining did not reveal any differences in the proportion of senescent cells in the DM1 and WT NSCs cultures (Supp. Fig. S2 ). Altogether, these results indicated that the reduced proliferative capacity of DM1-NSCs was not associated to an increase in either cell mortality or senescence.
Large cytoplasmic vacuoles were observed in DM1-NSCs, suggesting the induction of autophagy (Fig. 3a) . Confirming this functional phenotype, increased expression of the autophagic markers LC3B-II, p62 (also named SQSTM1) and ATG12 protein was observed in DM1-NSCs ( Fig. 3b-f ), as well as significantly increased expression of the lysosomal cathepsin B marker both at the mRNA and the protein level (Supp. Fig. S3 ). In addition, the nucleofection of a plasmid encoding the LC3-GFP fusion protein, used as a marker for autophagic vesicles and pre-autophagic compartments, showed in an increased number of DM1-NSCs harboring LC3-GFP aggregates, relative to controls ( Fig. 3c and 3d) . As a positive control, treatment of WT-NSC with either EBSS medium or chloroquine resulted in an increased number of cells containing LC3-GFP aggregates. No effect of chloroquine treatment was observed on DM1-NSCs suggesting that these cells could not accumulate additional autophagic vacuoles.
Alteration of mTOR signaling pathways in DM1 neural cells
To assess the central role of AKT/mTOR signaling pathways in both cell cycle control and autophagy, expression of their main components, namely Akt, AMPK, GSK3α/β and rpS6 (Ser235/236) (for ribosomal protein S6) was systematically analyzed. Gene expression and protein levels were unaltered for all of these components, when analyzed by quantitative PCR and western blotting, respectively ( Fig.4 and Supp. FigS4). In contrast, analysis of the posttranslational activation of these proteins through phosphorylation revealed major differences between DM1 and controls. Whereas phosphorylation of the upstream components Akt (Ser473) and AMPK (Thr172) appeared unaffected, the downstream GSK3α/β (Ser21/9) and rpS6 (Ser235/236 and Ser240/245) were decreased in DM1-NSCs ( Fig. 4a and 4b ) through a mechanism independent of a stress-induced activation of P53 (Supp. Fig S4) .
To eliminate the possibility of a non-specific effect of the growth factors present in the medium (i.e. EGF, FGF2 and BDNF) on mTOR signaling pathway activity, NSCs were starved for forty eight hours and then treated for one hour with each factor alone or in combination. No effect of EGF and/or BDNF was observed on phosphorylated Ser235/236-rpS6 levels. Treatment with FGF2 resulted in a dramatic increase in phosphorylated rpS6 (Ser235/236) through the activation of Phospho-Erk1/2, equally in DM1 and WT-NSCs ( Fig.   4c and 4e) . The effect of FGF2-mediated ERK1/2 activation on the phosphorylation of P-rpS6 was transient, as it disappeared forty eight hours after treatment. As all our experiments were performed forty eight hours after treatment with growth factors, these results suggest that a differential impact of growth factors present in the medium on mTOR signaling pathways in DM1-and WT-NSCs can be ruled out.
Molecular correlates of functional defects in DM1 neural cells
A potential link between the functional defects observed in DM1-NSCs for proliferation and autophagy and the decreased activation of mTOR signaling was explored by analyzing the functional consequences of a partial pharmacological blockade of the pathway in WT-NSCs. Cells were treated with rapamycin, a specific mTOR inhibitor. Rapamycin provoked a dramatic decrease in phosphorylated (Ser235/236)-rpS6 without substantial modulation of either phosphorylated (Ser473)-Akt, (Ser21)-GSK3α or (Ser9)-GSK3β (Fig. 5a and 5b and Supp. Fig. S4 ). Functional defects associated with this molecular alteration were reminiscent of the phenotype described above for DM1-NSCs, as rapamycin-treated WT-NSCs exhibited impaired proliferative capacity (Fig. 5c and 5d and Supp. Fig S4) and induction of autophagy, as shown by LC3-GFP aggregation after transfection with the fusion protein plasmid ( Fig. 5e and 5f ).
Association of mTOR signaling alterations with expression of the mutant DMPK gene was
controlled by transient transfection of WT-NSCs with a plasmid containing an extended stretch of 960 CTG repeats. Treated cells exhibited a profound decrease in P-rpS6 as well as P-GSK3β, which was consistent with our working hypothesis (Fig. 6a and 6b and Supp. Fig.   S5 ). The main consequence of the presence of an extended stretch of CUG repeats in DM1-NSCs is the decreased bioavailability of the MBNL1 protein due to its sequestration in intranuclear foci. To reproduce this phenomenon in WT-NSCs, MBNL1 gene expression was knocked down using specific siRNAs. MBNL1-depleted cells exhibited significantly decreased levels of P-rpS6 and, to a lesser extent, decreased levels of P-GSK3α/β (Ser21/9) ( Fig. 6b) . Conversely, overexpression of MBNL1 in DM1-NSCs elicited a partial restoration of the phosphorylation of Ser232/236-rpS6 (Fig. 6c ). These changes in MBNL1 expression in DM1 and WT-NSCs led to altered proliferation and autophagy ( Fig. 6d and 6e ).
DISCUSSION
The primary finding of the current study was the identification of an altered mTOR signaling pathway, which results in reduced proliferative capacity and induction of autophagy in neural cells derived from DM1 gene-carrying human embryonic stem cells. This alteration in the mTOR signaling pathway could be reproduced by reducing the bioavailability of the RNA-binding protein MBNL1 in WT cells, mimicking the defect associated to the expression of the DM1 mutation. The functional abnormalities associated with the altered mTOR pathway might contribute to the neurological aspects of this disease. This study further highlights the value of mutant gene-carrying human stem cell lines obtained from preimplantation genetically diagnosed embryos in helping to decipher the molecular mechanisms and the functional consequences related to these mutations.
Molecular mechanisms involved in DM1 pathophysiology have been mainly identified by using animal models. Few human cell culture models have been developed; most are based on the use of muscle precursor cells derived from congenital forms of DM1, which are characterized by very large stretches of CTG repeats (>2000). Myoblasts derived from congenital forms of DM1 have alteration in various cell cycle modulators, including p21 and cyclin D1 (Timchenko et al., 2001b; Timchenko et al., 2004) . They also exhibited premature senescence through a p16-dependent mechanism and defect in p38MAPK and ERK MEK (Bigot et al., 2009 ), leading to defective proliferation and differentiation (Beffy et al., 2010; Bigot et al., 2009; Timchenko et al., 2001b; Timchenko et al., 2004) . In addition, the induction of autophagy has been recently observed in myoblasts derived from congenital DM1 patients; a link to a p53-dependent inhibition of mTOR pathway in response to metabolic stress has been hypothesized (Beffy et al., 2010) .
Our results have in part confirmed these data, by extending them to DM1 neural precursor cells where altered proliferation and induction of autophagy were observed. However, molecular mechanisms responsible for those effects were not similar as neither persistent activation of the FGF2-dependent MEK-ERK pathway nor abnormal p53 activation was observed in DM1-NSCs. Therefore, the current results do not support the hypothesis of a cellular stress response in DM1 cells, which would be secondarily responsible for the mTOR signaling pathway alterations. Nevertheless, we cannot exclude the possibility that these discrepancies are due to the differences between either the cell types analyzed or the number of CTG repeats in the two cellular systems. Indeed, mTOR signaling was altered in the current study in the presence of only 1000 CTG repeats in DM1-NSCs or after transfection of a plasmid with 960 repeats in WT-NSCs, i.e. in conditions that are unlikely to be linked with congenital forms of the disease.
Conversely, our data point to a specific defect in the activity of the glycogen synthase kinase 3 (GSK3) being associated with the disease. GSK3 activity is inhibited through phosphorylation of serine 21 in GSK-3α and serine 9 in GSK-3β, which have been identified as targets of Akt and AMPK (Fang et al., 2000) . The inhibition of GSK3 may participate in the activation of mTOR, which results in the increased phosphorylation of rpS6 (Jastrzebski et al., 2007) . According to this cascade of events and in the absence of any alteration in the activation of Akt or AMPK in DM1 neural cells, the decreased mTOR-dependent phosphorylation of rpS6 can be directly associated to this decreased inhibition of GSK3.
Alternatively, as GSK3 acts as an integrator of Akt and Wnt signals, the observed alteration of the GSK3/mTOR pathway is related to a Wnt defect (Ma et al., 2010; Vigneron et al., 2011) .
Consistent with the results of the current study, alteration of GSK3 phosphorylation was also observed in a rat PC12 cell line expressing 90 CUG repeats, which resulted in altered expression and phosphorylation of Tau (Hernandez-Hernandez et al., 2006) . Given the crucial role of Tau in neurodegenerative diseases, further investigations into whether the decreased GSK3 phosphorylation observed in DM1-NSCs could lead to defects in Tau expression would be of interest.
Mechanisms by which the DM1 mutation can modulate the phosphorylation of specific molecular targets of the mTOR signaling pathways remain to be determined. Three main hypotheses may be proposed : 1) haploinsufficiency of the DMPK gene ;
2) alteration of the expression of neighboring genes such as SIX5 and DMDW (Klesert et al., 2000; Sarkar et al., 2000) ; 3) Toxic gain-of-function of the mutant mRNA because of the sequestration of proteins involved in RNA processing, such as the MBNL1 protein (Ranum and Cooper, 2006) . Whereas various evidences suggests that the toxic gain-of-function of the mutant RNA corresponds to the main mechanism by which the DM1 mutation causes the complex pattern of the disease, the contributions of each of these mechanisms are not mutually exclusive. As an example, insulin-resistance associated with DM1 has been correlated both to DMPK haploinsufficiency and to aberrant regulation of alternate splicing of the insulin receptor due to the loss of bioavailability of MBNL1 (Llagostera et al., 2007; Savkur et al., 2001) . The current results following gain-or loss-of-function of MBNL1 support the hypothesis of a potential role for a toxic RNA mechanism in mTOR signaling alterations that involves loss of MBNL1 bioavailability. Further studies will be required to determine the mechanism by which MBNL1 may modulate the GSK3/mTOR signaling pathway. However, it is worth mentioning that the effect of gain-and loss-of-function of MBNL1 is less pronounced on proliferation than on autophagy, which suggests the implication of other modulators in the proliferation phenotype. Accordingly, CUGBP1, another RNA-binding protein whose expression is affected by the presence of the DM1 mutation, has been shown to affect the expression of cell cycle inhibitor p21 expression in
DM1.
A large number of neurological abnormalities have been reported in patients both at clinical and histological levels (de Leon and Cisneros, 2008). Central nervous system involvement in DM1 reveals itself through cognitive impairment, hypersomnolence, and personality and behavioral disturbances (Abe et al., 1994; Delaporte, 1998; Meola et al., 2003; Modoni et al., 2008; Turnpenny et al., 1994) . Grey matter reduction has also been described in various cortical regions, the hippocampus and the thalamus of DM1 patients (Minnerop et al., 2008; Minnerop et al., 2011; Weber et al., 2010) . At the molecular level, nuclear aggregation of mutant mRNAs in combination with MBNL1 has been described in cortical and subcortical neuronal cells of DM1 patients post-mortem (Jiang et al., 2004) .
Alternative splicing of NMDAR1 (N-methyl-D-aspartate receptor1), APP (amyloid beta precursor protein) and microtubule-associated protein tau (MAPT) is abnormally regulated in DM1 brain tissue samples, even though direct involvement of MBNL1 in these splice defects has not been demonstrated (Jiang et al., 2004) . However, the functional consequences as well as the precise neuropathological contributions of these molecular abnormalities are still unclear. MBNL1 knock-out mice exhibit cognitive impairments, suggesting that MBNL1 loss-of-function might be implicated in the neuropathology of DM1 (Matynia et al., 2010) .
The MBNL1 knockout mouse model has also identified novel splicing defects in the brain, including Sorbs1, Dclk1 and Camk2d (Suenaga et al., 2012) , but these genes have not been associated to clinical symptoms, yet. Last, a very recent study using a MBNL2 knock-out mouse model suggests an essential role for this gene in the DM1 developing brain (Charizanis et al., 2012) . However, this conclusion needs to be qualified in the light of redundant functions of the different types of MBNL1 and MBNL2 proteins (Wang et al., 2012) .
The results of the current study shed some light on the neuropathology of DM1, as we have identified a MBNL1-dependent mTOR signaling defect, leading to functional abnormalities, in neural precursors that have been shown by previous authors to exhibit a telencephalic phenotype (Chambers et al., 2009) . Tentatively, and subject to further validation, one may relate the proliferation defects observed in DM1-NSCs to the reduced volume of the grey matter in DM1 patients. mTOR-dependent induction of autophagy may also participate in the neuropathology, as a similar process has been suggested to play a role in other neurologic disorders involving abnormal protein aggregations, such as Parkinson, Alzheimer and Huntington diseases (Garelick and Kennedy, 2010) .
MATERIALS AND METHODS
Cell cultures
hES cells were propagated as previously described (Marteyn et al., 2011) . The differentiation of hES into NSC was performed by using a SMAD inhibitor protocol (Chambers et al., 2009) .
Briefly, hES colonies were mechanically dissociated and incubated in suspension with N2B27 medium containing: 1:2 of DMEM/F12 medium with Glutamax I; 1:2 of Neurobasal medium; N2 supplement; B27 supplement without vitamin A; β-Mercaptoethanol (all from Invitrogen).
The following were also added: human recombinant Noggin, a BMP pathway inhibitor, used at 300 ng/mL (PeproTech); SB-431542, a TGFβ pathway inhibitor, used at 20 µM (Tocris); Y-27632, a ROCK inhibitor, used at 20 µM (Calbiochem). After 6 hours, aggregates were transferred in a dish pre-coated with 0.01% Polyornithine (Sigma) and Laminin 1 ng/mL (Sigma) and maintained with medium (without Y-27632). After the appearance of neural rosettes following 8-10 days of differentiation, the medium was replaced by the N2B27 medium supplemented with EGF (Epidermal Growth Factor) at 10 ng/mL (R&D Systems); FGF2 (Fibroblast Growth Factor) at 10 ng/mL (PeproTech); hBDNF (human Brain-Derived Neurotrophic Factor) at 20 ng/mL (R&D Systems). For differentiation into neurons, NSC cells were seeded at a density of 50,000 cells per cm² on Polyornithine/Laminin coated dishes in N2B27 medium containing hBDNF but without EGF and FGF2. Medium was changed every other day for 20 days. Treatment with chemical compounds such as rapamycin (Cell Signaling), chloroquine and bafylomycin (Sigma) was performed following the manufacturer's instructions.
Senescence, apoptosis and proliferation assay
Senescence assay was performed using a senescence detection kit based on β -galactosidase activity as per the manufacturer's instructions (Abcam). Apoptosis assay was performed using Vybrant Apoptosis Assay Kit (Molecular Probes) according to manufacturer's recommendations and proliferation was measured using CTG Cell Titer Glo® (Promega).
Briefly, at Day 1 NSCs were plated in 96-well plates in 100µL media at 2,000 cells/cm 2 .
CellTiter-Glo ® reagent (Promega) was added to the cells and the bioluminescence signal was read 40 min later on an AnalystGT microplate reader (Molecular devices).
Mean Doubling time (Tmean) was calculated for each cell line as followed:
Number of cells at a defined time of the experiment was calculated using calibration curve obtained by serial dilution of a defined number of cells and correlated to luminescence signal (proportional to [ATP] intracellular concentration).
RNA extraction and Real-Time RT-PCR
Total RNA from cells was extracted using the "RNeasy Mini Kit Protocol" (Qiagen). Reverse transcription was performed with SuperScript III reverse transcriptase (Invitrogen) and realtime PCR were performed with SyberGreen PCR Master Mix (Applied Biosystems) on a Chromo4 Real-Time system (Bio-Rad) as previously described (Marteyn et al., 2011) .
Primers are listed in Supp. Table S1 .
Nucleofection experiment with p960-CTG, siMBNL1 and expression plasmid MBNL1
The sequence encoding the 43kDa isoform of MBNL1 inserted in the pCDNA3.1 vector and the plasmid (CTG) 960 were kindly provided by Dr Nicolas Charlet (CERBM-GIE, Illkirch, France). The plasmid expressing the LC3-GFP fusion protein was kindly provided by Prof.
Codogno (INSERM U984, Chatenay-Malabry, France). The siRNA sequence for MBNL1 knock-down was previously described (Dansithong et al., 2005) .
These expression vectors and siRNAs were nucleofected into NSCs using the "Rat Neural Stem Cell Nucleofector Kit" (Lonza) according to the manufacturer's instructions.
Immunocytochemistry and Fluorescent in Situ Hybridization (FISH)
Immunocytochemisty and fluorescent in situ hybridization were performed as previously described (Marteyn et al., 2011) . Primary antibodies are listed in Supp. Table S2 .
Immunostaining was analyzed by epifluorescence microscopy with the Zeiss Imager Z1 and the Zeiss Axiovert 40CFL, and images were captured with the Zeiss Axiocam mRM.
ArrayScan analysis
Number of nuclei with foci, number of foci per nucleus and number of cells with at least two LC3-eGFP positive autophagosomes were counted using the ArrayScan VTI HCS Reader (Cellomics). Data were examined using the Cell Selecting software (Cellomics) as previously described (Marteyn et al., 2011) .
SDS Poly-Acrylamide Gel Electrophoresis and Western Blotting
Cells were lyzed in RIPA lysis buffer (Sigma) supplemented with antiprotease cocktail (Sigma) and antiphosphatase (Roche). Nuclear and cytoplasmic fractions were extracted using the NE-PER Kit (Thermoscientific). Protein concentration of the cell extracts was determined at 562 nm using the Pierce® BCA Protein Assay Kit (Perbio Thermo Scientific) according to the manufacturer's instructions and using a plate analyzer (Biotek). SDS Poly-Acrylamide Gel Electrophoresis (SDS-PAGE) was performed using NuPAGE® Novex 4-12% Bis-Tris Gels (Invitrogen); 10 to 30 µg of total protein was loaded per lane. iBlot® Gel Transfer Stack (Invitrogen) was used for the transfer onto nitrocellulose membranes. Membranes were blocked with 5% non-fat milk in Phosphate Buffered Saline containing 0.1% Tween 20 (PBST) for 1 hour (except for MBNL1 antibody which requires SVF 2% in PBST), then incubated overnight at 4°C in 5% non-fat milk in PBST (except for MBNL1 : PBST only) with primary antibodies at the appropriate dilution. The antibodies used are listed in Supp. Table S2 . Immunoreactive bands were revealed by using Amersham ECL Plus™ Western Blotting Detection Reagents (GE Healthcare). Equal protein loading was verified by the detection of Actin. Quantification was performed using the Image J software (NIH).
Statistical analysis
All the data are given as mean ± standard error of the mean (SEM) and were analyzed by GraphPad Prism 6.0 software. All the statistical tests were performed at least 3 times and oneway ANOVA with Dunnett's post hoc test was used. Nucleofection of DM1-and WT NSCs with a plasmid expressing a LC3-GFP fusion for 48 hours (VUB03_DM and VUB01_WT, respectively). d. Increased number of cells containing LC3-GFP dots in the cytoplasm of DM1-NSCs. EBSS and chloroquine at 50µM were used as a positive control. Data are presented as a percentage of positive cells quantified by the automated ArrayScan Imager. e. Detection by immunostaining of two autophagic markers p62 and ATG12 in WT and DM1-NSCs (VUB03_DM and VUB01_WT, respectively). Statistical data are expressed as mean ± SEM using at least 3 independent samples. One-way ANOVA with Dunnett's post hoc test was performed, ns: not significant, *: p-value < 0.05, ** p-value < 0.01. *** p-value < 0.001. Figure 4 : mTOR signaling pathway is defective in DM1-NSCs a. Expression level of key modulators of Akt/mTOR signaling in DM1-NSCs and WT-NSCs including: Phospho(Ser473)-Akt, Phospho(Thr172)-AMPKα, Phospho(Ser21/9)-GSK3α/β, and Phospho(Ser235-236)-Ribosomal protein S6 (rpS6) and the corresponding total forms. Cell lysates were obtained after 48 hours of culture. b. Decreased phosphorylation of S6 Ribosomal protein at Serine 235-236 and Serine 240-245 in DM1-NSCs when compared to control NSCs after 48 hours of culture. c. Effect of the different growth factors required for NSC culture (i.e. EGF (epidermal growth factor), FGF2 (fibroblast growth factor), BDNF (Brain derived neurotrophic factors)) on the phosphorylation of P-rpS6 (Ser235-236). DM1-NSCs and WT-NSCs were growth factor starved for 48 hours and subsequently treated for one hour with or without each of the growth factors. d. FGF2 dose-response analysis after growth factor starvation and treatment with FGF2 from 1 to 100 nM for 1 hour of DM1-and WT-NSCs. The expression level of rpS6 and ERK1/2 was analyzed. e. Kinetic of FGF2 treatment on DM1-and WT-NSCs for the expression of rpS6 and ERK1. Cells were starved for 48 hours and then treated for various durations with FGF2 (10 nM). Western blot were quantified using NIH Image J software and quantitative data are presented as phosphorylated form normalized to their total form. VUB03_DM cells were used as source for DM1-NSCs. Statistical data are expressed as mean ± SEM using three independent samples. One-way ANOVA with Dunnett's post hoc test was performed, ns: not significant, *: p-value < 0.05, ** p-value < 0.01 *** p-value < 0.001. Figure 5 : mTOR defect is correlated to decreased proliferation and induction of autophagy in DM-NSCs a. Effect of rapamycin treatment on the expression of key players of the Akt/mTOR signaling pathway in DM1-and WT-NSCs, determined by western blot analysis. b. Detection, by immunofluorescence, of P-rpS6 (Ser235-236) in DM1-and WT-NSCs after treatment with rapamycin (10nM) for 48 hours c. Effect of rapamycin treatment (10 nM for 4 days) on proliferation rate of WT-NSCs as determined by measuring intracytoplasmic ATP. d. Quantification of the proliferation index of the WT-NSCs with or without rapamycin treatment (10 nM) for four days. Data are presented as the mean of signal [ATP] at day x+1/x compared to the control condition (arbitrary 100%) e. Detection of autophagy using anti-LC3B antibody in WT-NSCs treated with rapamycin (10 nM) or treated with chloroquine (50 µM) for 6 hours. f. Quantification of autophagosomes after transfection of WT-NSCs with a plasmid expressing LC3-GFP fusion protein for 48 hours and treatment with rapamycin and/or chloroquine for 6 hours. Data are presented as a percentage of positive cells quantified by the automated ArrayScan Imager. Statistical data are expressed as mean ± SEM using at least 3 independent samples. One-way ANOVA with Dunnett's post hoc test was performed, ** p-value < 0.01. *** p-value < 0.001.
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